TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by excessive production of extracellular matrix by fibroblasts on skin and internal organs. Although Th2 cells have been involved in fibroblast stimulation, hyperactivated B cells may also play an important role. Regulatory B cells (Bregs) are cells capable of inhibiting inflammatory responses and controlling autoimmune diseases. Although many Breg populations have in common the ability to produce high amounts of IL-10, a unique surface marker defining most human Bregs is lacking. It has been described in mice that T cell Ig and mucin domain protein 1 (TIM-1) is an inclusive marker for Bregs, and that TIM-1+ B cells are able to prevent the development of autoimmunity. The aim of this work was to evaluate TIM-1 as a marker for human IL-10 + Bregs, and to determine whether TIM-1+ B cells are defective in SSc patients. SSc patients (n = 39) and 53 healthy subjects were recruited. TIM-1 and IL-10 expression was assessed in resting or activated peripheral blood CD19 + B cells by flow cytometry. The regulatory function of TIM-1 + or activated B cells from SSc patients and healthy subjects was assessed in autologous and allogenic co-cultures with CD4 + T cells, where T cell proliferation and IFN-γ, IL-17, TNF-α and IL-4 production by T cells was measured by flow cytometry. TIM-1 and IL-10 were preferentially expressed in transitional B cells, but were upregulated in naïve and memory B cells upon stimulation. The frequency of transitional TIM-1 + IL-10 + B cells was significantly decreased in SSc patients compared to healthy controls. In addition, activated B cells from SSc patients induced stronger allogenic Th1 and Th2 responses than activated B cells from healthy controls. Finally, TIM-1 + B cells, including transitional and non-transitional cells, exhibited a higher CD4 + T cell suppressive ability than TIM-1 − B cells in healthy controls, but not in SSc patients. TIM-1 is a unique marker for the identification of a human IL-10 + Breg subpopulation which is partially superimposed with transitional B cells. Alterations in TIM-1 + B cells could contribute to the development of autoimmune diseases such as SSc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blair, P. A., Noreña, L. Y., Flores-Borja, F., Rawlings, D. J., Isenberg, D. A., Ehrenstein, M. R., & Mauri, C. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.009 · Cited by 1,574 · cited 6×
“As previously described [7], transitional B cells were the subpopulation most enriched in IL-10 cells (Fig.”
BackgroundResultSelf-citationRegulatory B Cells: Origin, Phenotype, and Function
Rosser, E. C., & Mauri, C. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.005 · Cited by 1,455
Self-citationShen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048 · cited 1×
“The maintenance of immune tolerance and prevention of autoimmunity is exerted by different subpopulations of regulatory B cells (Bregs), which include type 2 marginal zone precursors [3], CD1dCD5 B10 cells [4], plasmablasts [5], and plasma cells [6] in mice; and CD24CD38 transitional B cells [7], CD24CD27 B10 cells [8…”
BackgroundDing, Q., Yeung, M., Camirand, G., Zeng, Q., Akiba, H., Yagita, H., Chalasani, G., Sayegh, M. H., Najafian, N., & Rothstein, D. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46274 · Cited by 462 · cited 6×
“Also, TIM-1+ B cells inhibit Th1 and Th17 responses in vivo in the EAE model [13].”
BackgroundInfluential
Cited by
Sanz, I., Wei, C., Jenks, S. A., Cashman, K. S., Tipton, C., Woodruff, M. C., Hom, J., & Lee, F. E.-H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02458 · Cited by 569
Immunosuppressive Mechanisms of Regulatory B Cells
Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinika, K., Aguillón, J. C., & Aravena, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611795 · Cited by 399
Self-citationTargeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
“By contrast, several studies on RA (206, 210–212), SLE (204), systemic sclerosis (SSc) (213, 214), and MS (215–217) patients have shown a reduced number of peripheral IL-10-producing B cells compared with that in the controls.”
Organization of the skin immune system and compartmentalized immune responses in infectious diseases
Quaresma, J. A. S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-18 · Cited by 149
Metadata
- Authors
- Aravena, O., Ferrier, A., Menon, M., Mauri, C., Aguillón, J. C., Soto, L., & Catalán, D.
- Venue
- Arthritis Research & Therapy
- Published
- 2017-01-19
- Volume
- 19
- Issue
- 1
- Pages
- 8-8
- ISSN
- 1478-6354 (ISSN-L)
- 1478-6362
- OpenAlex
- W2578573294
- Cited by
- 105
- References
- 4
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients. https://app.cochat.ai/papers/10.1186/s13075-016-1213-9
- The paper
- Aravena, O., Ferrier, A., Menon, M., Mauri, C., Aguillón, J. C., Soto, L., & Catalán, D. (2017). TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-016-1213-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.